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Summary
Objective We are aware of no study examining the effects of
selenium supplementation on metabolic profiles of patients with
polycystic ovary syndrome (PCOS). This study was conducted to
evaluate the effects of selenium supplementation on glucose
homeostasis parameters and lipid concentrations in women with
PCOS.
Design, patients and measurements This randomized, dou-
ble-blind, placebo-controlled trial was conducted among 70
women diagnosed with PCOS and aged 18–40 years old. Partici-
pants were randomly divided into two groups to receive 200 lg
per day selenium supplements (N = 35) or placebo (N = 35) for
8 weeks. Fasting blood samples were taken at baseline and after
8 weeks intervention to quantify glucose, insulin and lipid con-
centrations.
Results After 8 weeks of intervention, subjects who received sele-
nium supplements had significantly decreased serum insulin levels
(2983  4729 vs +907  7712 pmol/l, P = 0013), homeo-
stasis model of assessment-insulin resistance (HOMA-IR)
(115  181 vs +042  309, P = 0011), homeostatic model
assessment-beta-cell function (HOMA-B) (1906  3095 vs
+455  4799, P = 0017) and increased quantitative insulin sen-
sitivity check index (QUICKI) (+003  004 vs +00009  005,
P = 0032) compared with placebo. In addition, supplementation
with selenium resulted in a significant reduction in serum triglyce-
rides (014  055 vs +011  030 mmol/l, P = 0025) and
VLDL-C concentrations (003  011 vs +002  006 mmol/l,
P = 0025) compared with placebo.
Conclusions In conclusion, 200 microgram per day selenium
supplementation for 8 weeks among PCOS women had beneficial
effects on insulin metabolism parameters, triglycerides and VLDL-C
levels; however, it did not affect FPG and other lipid profiles.
(Received 11 November 2014; returned for revision 3 December
2014; finally revised 5 December 2014; accepted 7 December 2014)
Introduction
The polycystic ovary syndrome (PCOS) is a common endocrine
disorder associated with metabolic complications affecting
5–10% of reproductive-age women.1 Women with PCOS usually
have intrinsic insulin resistance (IR), increased risk of cardiovas-
cular disease (CVD), hyperleptinemia and other metabolic disor-
ders such as hypertension, gestational diabetes (GDM), type 2
diabetes mellitus (T2DM)2 and dyslipidemia.3 It is still under
debate whether nonobese women with PCOS are insulin resis-
tant. While there is no difference in insulin resistance between
nonobese and obese patients in some studies,4 others have not
been able to demonstrate insulin resistance in lean PCOS
women.5 In addition, several studies have reported that the
prevalence of CVD risk factors is higher in PCOS women com-
pared with age-matched controls,6 which in turn led to the
assumption that PCOS female also run an increased risk of mor-
tality, with most of the events predicted to occur during the
postmenopausal years. In a study by Dahlgren et al.7 was
observed a sevenfold increased risk of myocardial infarction
(MI) in PCOS women compared to age-matched referents.
Selenium is an essential micronutrient, which plays an impor-
tant role in redox reactions including glutathione peroxidase and
thioredoxin reductase.8 More recently, evidence has also been
presented that selenium could affect carbohydrate and fat metab-
olism. Induced selenium deficiency has resulted in an increase in
plasma glucose levels in healthy rats and to further elevation of
plasma glucose levels in diabetic rats.9 In vitro and in vivo studies
have shown that selenium possesses insulin-like actions.10 In a
study by Alizadeh et al.11 demonstrated that the administration
of 200 lg/day selenium supplements for 6 weeks resulted in a sig-
nificant decrease in serum insulin levels and homeostatic model
of assessment for insulin resistance (HOMA-IR) among women
with central obesity. In addition, a significant decrease in total
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cholesterol and triglyceride levels was observed in male New Zea-
land white rabbits after selenium intake.12 However, a 3-month
supplementation with 200 lg selenium supplements daily in dia-
betic patients did not influence serum insulin levels and led to
increased fasting plasma glucose (FPG) levels.13
Beneficial effects of selenium supplementation on improved
glucose homeostasis and lipid profiles might result from its
effect on inhibiting the expression of cyclooxygenase (COX)-2
and P-selectin.14 In addition, selenium may reduce insulin resis-
tance through inhibiting the production of inflammatory cyto-
kines including tumour necrosis factor-a (TNF- a) and IL-1.15
Therefore, we hypothesized that selenium supplementation
might affect metabolic status of women with PCOS. We are
aware of no study that evaluated the effect of selenium supple-
mentation on glucose homeostasis parameters and lipid profiles
in patients with PCOS. This study aimed to investigate the effect
of selenium supplementation on metabolic profile of PCOS
women.
Subjects and methods
Participants
This study was a randomized, double-blind, placebo-controlled
clinical trial that was performed from August 2014 to October
2014 among the women with PCOS (according to Rotterdam
criteria) referred to the Research and Clinical Center for Infertil-
ity and Kossar Hospital, Arak, Iran. Individuals were eligible for
participation if they were aged 18–40 years and met the Rotter-
dam criteria for PCOS. Diagnosis of PCOS was performed
according to the Rotterdam criteria16: those with two of the fol-
lowing criteria were considered as having PCOS: oligo- and/or
anovulation, hyperandrogenism and polycystic ovaries. Menstrual
irregularity was assessed as the presence of chronic amenorrhoea
or a menstrual cycle length of less than 21 days or more than
35 days, or more than 4 days variation between cycles. Biochem-
ical hyperandrogenism was evaluated by increased levels of
serum androgens (male hormones) including androstenedione
and testosterone. Clinical hyperandrogenism was assessed as the
self-reported degree of hirsutism using the modified Ferriman
Gallwey (mF-G) scoring method based on a chart displaying
degree of hair growth in nine regions17 or acne. In this method,
hair growth is rated from 0 (no growth of terminal hair) to 4
(extensive hair growth) in each of the nine locations. In addi-
tion, all individuals attending the centre were first examined by
the study gynaecologist and after diagnosis of PCOS in all sub-
jects; they were instructed to fill mF-G scoring form validated
for the Iranian population.18 The self-reported hirsutism was
rechecked and confirmed by the study gynaecologist. Polycystic
ovaries were diagnosed by ultrasonography (US) in participants
with menstrual dysfunction and/or hirsutism. According to the
Rotterdam criteria, 12 or more small follicles should be seen in
an ovary on ultrasound examination. A total of 990 women
attended gynaecology clinic, affiliated with Arak University of
Medical Sciences (AUMS), were screened for PCOS. Subjects
who reported menstrual irregularity and/or had a mF-G score of
8 or higher were invited for clinical examination. Those who did
not meet these criteria were not further examined and were
deemed not to have PCOS. Finally, 70 women met the inclusion
criteria based on Rotterdam criteria and were enrolled in the
study (Fig. 1). In this study, the primary outcome variable was
HOMA-IR. For estimating sample size, we used the standard
formula suggested for parallel clinical trials by considering type
one error (a) of 005 and type two error (b) of 020
(power = 80%). Based on a previous study,11 we used 164 as
SD and 120 as the difference in mean (d) of HOMA-IR as key
variable. Based on this, we needed 30 subjects in each group.
Considering 5 dropouts in each group, the final sample size was
determined to be 35 patients per group. The women who were
menopause, consumed selenium supplements and metformin in
Randomized (N = 70) 
Allocated to placebo (N = 35) 
Lost to follow-up (N = 2) 
-Withdraw (N = 2) 
Analyzed (N = 35) 
Allocated to intervention (N = 35) 
Lost to follow-up (N = 3) 
-Withdraw (N = 3) 
Analyzed (N = 35) 
Assessed for eligibility (N = 990) 
Excluded (N = 920)  
- Not meeting inclusion criteria (N = 900)  
- Not living in Kashan (N = 20)  
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Fig. 1 Summary of patient flow diagram.
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the last 3 months, used tobaccos, were diabetic or hypothyroid-
ism, followed a special diet or consumed effective drugs on hor-
monal profile such as oral conceptive (OCP), and ovulation
induction agents were excluded in this study. These variables
may affect markers of insulin resistance or lipid profiles. This
study was carried out according to the guidelines laid down in
the Declaration of Helsinki. The ethical committee of AUMS
approved the study, and informed written consent was obtained
from all participants. The trial was registered in the Iranian web-
site (www.irct.ir) for registration of clinical trials (IRCT code:
IRCT201408155623N25).
Study design
At study baseline and after stratification for pre-intervention
BMI (<25 and ≥25 kg/m2) and age (<30 and ≥30 year), sub-
jects were randomly divided into two groups to receive either
200 lg daily selenium supplements as tablet (N = 35) or pla-
cebo (N = 35) for 8 weeks. Selenium supplements and its pla-
cebos (cellulose) were manufactured by Nature Made
Pharmaceutical Company (Los Angeles, CA, USA) and Barij
Essence Pharmaceutical Company (Kashan, Iran), respectively.
Supplements and placebos were in the same form of package,
and the patients and researcher were not aware of the content
of the pack until the end of analysis. Individuals were ran-
domized, in a 1:1 ratio. Random assignment was performed
by the use of computer-generated random numbers. Randomi-
zation and allocation were concealed from the researcher and
participants until the main analyses were completed. A trained
midwife at gynaecology clinic did the randomized allocation
sequence, enrolled participants and assigned participants to
interventions. At the start of the study, the individuals were
asked to maintain their usual diet and level of physical activ-
ity throughout the study period as well as not to receive any
lipid-lowering medications and medications that might affect
their reproductive physiology during the 8-week intervention.
The use of selenium supplements and placebos throughout
the study was checked through asking participants to bring
the medication containers. To increase the compliance, all
patients were receiving short messages on their cell phones to
take the supplements each day. All participants provided three
dietary records (one weekend day and two weekdays) and
three physical activity records to make sure that they main-
tained their usual diet and physical activity during interven-
tion. Both dietary and physical activity records were obtained
at week 2, 4 and 6 of intervention. The dietary records were
based on estimated values in household measurements. To
obtain nutrient intakes of participants based on these 3-day
food diaries, we used Nutritionist IV software (First Databank,
San Bruno, CA, USA) modified for Iranian foods.
Assessment of variables
Height and weight (Seca, Hamburg, Germany) were measured
using standard protocols with subjects in light gown and with-
out shoes. Body mass index (BMI) was calculated as weight
(kg) divided by height squared (m2). Waist circumference was
measured at the minimum circumference between the iliac
crest and the last rib. Hip circumference was measured at the
maximum protuberance of the buttocks. All measurements
were taken by the same person to reduce subjective errors.
Fasting blood samples (10 ml) were collected before and after
8-week intervention at Arak reference laboratory in an early
morning after an overnight fast. Blood samples were immedi-
ately centrifuged (Hettich D-78532, Tuttlingen, Germany) at
1465 g for 10 min to separate serum. Then, the samples were
stored at 80 °C before analysis at the AUMS reference labora-
tory.
Outcomes
As insulin resistance is the most important variable in PCOS
patients, primary outcomes considered markers of insulin resis-
tance in this study. Secondary outcomes were lipid profiles.
Commercial kits were used to measure fasting plasma glucose
(FPG), serum cholesterol, triglycerides, VLDL-C, LDL-C and
HDL-C concentrations (Pars Azmun, Tehran, Iran). All inter-
and intra-assay CVs for FPG and lipid profiles measurements
were <5%. Serum insulin was assayed by ELISA kit (Monobind,
CA, USA). The intra- and interassay CVs for serum insulin were
30% and 51%, respectively. HOMA-IR, homeostatic model
assessment-beta-cell function (HOMA-B) and the quantitative
insulin sensitivity check index (QUICKI) were calculated based
on suggested formulas.19 Measurements of glucose, lipid concen-
trations and insulin were taken in a blinded fashion, in dupli-
cate, in pairs (before/after intervention) at the same time, in the
same analytical run, and in random order to reduce systematic
error and interassay variability.
Statistical methods
We used Kolmogorov–Smirnov test to examine the normal
distribution of variables. The intention-to-treat (ITT) analysis
of the primary study end-point was carried out for all the ran-
domly allocated participants. Missing data from dropped out
participants were imputed using the method of ‘Last Observa-
tion Carried Forward’. To determine the effects of selenium
supplementation on insulin metabolism parameters and lipid
profiles, one-way repeated measures ANOVA was used to evaluate
the between-group changes in variables during the study. In
this analysis, the treatment was regarded as between-subject
factor, and time with two time-points (baseline and week 8 of
intervention) was considered as within-subject factor. To assess
whether the magnitude of the change in dependent variables
depended on the baseline values, age and baseline BMI, we
controlled all analyses for baseline values, age and baseline
BMI to avoid the potential bias that might have resulted. These
analyses were also carried out using one-way repeated measures
analysis of variance. A P-value <005 was considered statisti-
cally significant. All statistical analyses were carried out using
the Statistical Package for Social Science version 17 (SPSS Inc.,
Chicago, IL, USA).
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Results
In the present study, 70 women met the inclusion criteria based
on Rotterdam criteria and were enrolled in the study. The
groups were well-matched for age and BMI. Among individuals
in the selenium group, three women [withdraw due to personal
reasons (N = 3)] and in the placebo group, two women [with-
draw due to personal reasons (N = 2)] did not complete the
trial. However, as the analysis was carried out based on ITT, all
70 PCOS women were included in the final analysis. On average,
the rate of compliance in our study was high, such that higher
than 90% of tablets were taken throughout the study in both
groups. No side effects were reported following the consumption
of selenium supplements in patients with PCOS throughout the
study.
Mean baseline BMI of study participants was 252  39 kg/m2
(range: 160–350 kg/m2). Mean age and height of study partici-
pants were not statistically different between selenium and pla-
cebo groups. Baseline weight and BMI as well as their means
before and after intervention were not significantly different com-
paring the two groups (Table 1).
Based on the 3-day dietary records obtained throughout the
intervention, no statistically significant difference was seen
between the two groups in terms of dietary intakes of energy,
carbohydrates, proteins, fats, saturated fatty acids (SFA), polyun-
saturated fatty acids (PUFA), monounsaturated fatty acids
(MUFA), cholesterol, total dietary fibre (TDF) and selenium
(Table 2).
After 8 weeks of intervention, subjects who received selenium
supplements had significantly decreased serum insulin levels
(2983  4729 vs +907  7712 pmol/l, P = 0013), HOMA-
IR (115  181 vs +042  309, P = 0011), HOMA-B
(1906  3095 vs +455  4799, P = 0017) and increased
QUICKI (+003  004 vs +00009  005, P = 0032) com-
pared with placebo (Table 3). In addition, supplementation with
selenium resulted in a significant reduction in serum triglyce-
rides (014  055 vs +011  030 mmol/l, P = 0025) and
VLDL-C concentrations (003  011 vs +002  006 mmol/l,
P = 0025) compared with placebo. We did not see any signifi-
cant effects of selenium supplementation on FPG, other lipid
profiles and waist and hip circumference. Within-group changes
showed a significant reduction in serum insulin levels
(P = 0001), HOMA-IR (P = 0001), HOMA-B (P = 0001) and
a significant rise in QUICKI (P = 0002) in the selenium group.
In addition, within-group changes revealed a significant increase
in serum triglycerides (P = 0047), VLDL-C (P = 0047) and a
significant reduction in LDL-C concentrations (P = 0023) in
the placebo group.
Baseline levels of FPG were significantly different between the
two groups. Therefore, we controlled the analyses for the base-
line levels. However, after this adjustment no significant changes
in our findings occurred, except for FPG (P = 0009) (Table 4).
Additional adjustments for age and baseline BMI did not affect
our findings, except for FPG (P = 0010).
Discussion
The present study evaluated the effects of selenium supplemen-
tation on insulin metabolism parameters and lipid profiles
among women with PCOS. The major finding was that sele-
nium supplementation improved insulin function and decreased
triglycerides and VLDL-C levels in PCOS subjects. To the best
of our knowledge, this study is the first that reports the effect
of selenium supplementation on metabolic status in women
with PCOS. In the current study, no side effects were reported
after selenium supplementation in patients with PCOS through-
out the study. It must be considered that mean dietary plus
supplemental selenium intake was lower in our study partici-
pants than upper limits (400 lg). However, data on the effects
of selenium supplementation on health status even in subjects
with high-dietary selenium intake are conflicting. For instance,
in a study by Burk20 was seen that intake of moderate (approx-
imately 200 lg/day) to large (approximately 600 lg/day) sele-
nium supplements as selenomethionine was safe among
Table 1. General characteristics of study participants
Placebo group
(N = 35)
Selenium group
(N = 35) P*
Age (year) 257  48 254  51 080
Height (cm) 1633  65 1631  55 092
Weight at study
baseline (kg)
671  110 667  100 087
Weight at
end-of-trial (kg)
666  108 659  98 080
Weight change (kg) 05  14 08  08 045
BMI at study
baseline (kg/m2)
252  41 250  37 087
BMI at
end-of-trial (kg/m2)
250  40 248  36 081
BMI change (kg/m2) 02  05 02  03 053
Data are means  SD.
*Obtained from independent t-test.
Table 2. Dietary intakes of study participants throughout the study
Placebo group
(N = 35)
Selenium group
(N = 35) P*
Energy (kcal/day) 2402  155 2364  181 038
Carbohydrates (g/day) 3257  329 3231  426 079
Protein (g/day) 876  92 848  184 046
Fat (g/day) 871  129 850  180 060
SFA (g/day) 260  58 240  65 022
PUFA (g/day) 282  71 281  68 095
MUFA (g/day) 230  48 235  80 075
Cholesterol (mg/day) 2251  1175 2149  1399 076
TDF (g/day) 184  47 179  48 067
Selenium (lg/day) 585  80 561  105 033
Data are means  SD.
SFA, saturated fatty acid; PUFA, poly unsaturated fatty acid; MUFA,
mono unsaturated fatty acid; TDF, total dietary fibre.
*Obtained from independent t-test.
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volunteers ages ≥18 years for 16 weeks. However, some studies
have reported hair loss and dermatitis as the adverse effects of
selenium supplementation.21 Nonetheless, further studies are
required about potential toxicity/teratogenicity of long-term
increased selenium intake.
Patients with PCOS are susceptible to insulin resistance-
related condition including hirsutism, increased inflammatory
factors, hypertension, increased lipid profiles and increased risk
of CVD.22 The current study demonstrated that taking selenium
supplements for 8 weeks in women with PCOS resulted in a sig-
nificant decrease in serum insulin levels, HOMA-IR, HOMA-B
and a significant rise in QUICKI compared with placebo, but
did not influence FPG levels. Few studies have examined the
effects of selenium supplementation on insulin metabolism
parameters. In line with our study, in a study by Alizadeh
et al.11 was seen a significant decrease in serum insulin levels
and HOMA-IR score following the administration of 200 lg per
day selenium supplements among women with central obesity
for 6 weeks. In addition, oral selenate administration for
9 weeks in diabetic db/db mice significantly increased plasma
insulin concentrations.23 Campbell et al.24 demonstrated that
selenium stimulated pancreatic beta-cell gene expression and
enhanced islet function in cell culture. In contrast to our find-
ings, some studies did not observe such favourable effect of sele-
nium supplementation on insulin function. For instance, in a
study by Faghihi et al.13 found no significant difference in serum
insulin levels following the intake of selenium supplements
among diabetic patients for 3 months. Hyperinsulinism and
insulin resistance are frequent findings in PCOS patients, and
these traits have cause–consequence relationships with increased
risk of CVD,25 GDM and T2DM2 as well as dyslipidemia.3 A
previous meta-analysis has reported that selenium concentrations
were inversely associated with coronary heart disease risk in
observational studies.26 Other randomized trials which have
examined the effect of selenium supplements in combination
with other vitamins or minerals on CVD end-points have
yielded inconclusive findings.27,28 Beneficial effects of selenium
supplementation on improved insulin metabolism parameters in
the present study might have been resulted from its effect on
inhibiting the expression of COX-2 and P-selectin.14 In addition,
selenium has insulin-like properties and may act as a potential
antidiabetic agent.10 Selenium can also improve insulin function
through the inhibition of inflammatory cytokines including
TNF-a and IL-1.15
Findings from the current study revealed that taking selenium
supplements in patients with PCOS has resulted in a significant
decrease in serum triglycerides and VLDL-C levels compared
with placebo, but did not affect other lipid profiles. In line with
our findings, a significant decrease in serum triglycerides levels
after intake of 200 lg per day selenium supplements among
women with central obesity for 6 weeks, but did not affect other
lipid profiles.11 Furthermore, selenium supplementation led to a
significant decrease in triglyceride levels in male New Zealand
white rabbits12 and male mongrel rabbits.29 Specifically, sele-
nium supplementation was reported to decrease the level of tri-
glycerides in Sprague-Dawley rats after 4 months.30 However,
Cheung et al.31 showed that vitamins E and C, beta-carotene
and selenium supplementation tended to increase levels of
serum very low-density lipoproteins (TG-rich lipoproteins)
among coronary artery disease (CAD) patients for 12 months.
In addition, 100 lg daily selenium supplementation in pregnant
women did not affect cord-blood total LDL-C and HDL-C levels
and led to increased serum triglycerides.32 Different study
designs, different dosages of selenium used, lack of considering
Table 3. The effect of selenium supplementations on glucose metabolism and lipid profiles
Placebo group (N = 35) Selenium group (N = 35)
P†Wk0 Wk8 Change Wk0 Wk8 Change
FPG (mmol/l) 515  039 514  046 001  033 491  052 468  065 023  075 0116
Insulin (pmol/l) 7358  5950 8265  8250 907  7712 8069  4228 5086  3283* 2983  4729 0013
HOMA-IR 278  225 320  342 042  309 300  169 185  122* 115  181 0011
HOMA-B 4487  3975 4942  4974 455  4799 5036  2667 3130  2226* 1906  3095 0017
QUICKI 034  003 034  004 00009  005 033  003 036  003* 003  004 0032
Triglycerides (mmol/l) 130  059 141  070* 011  030 126  073 112  048 014  055 0025
VLDL-C (mmol/l) 026  011 028  014* 002  006 025  014 022  009 003  011 0025
Total cholesterol (mmol/l) 440  076 425  076 015  062 408  094 393  087 015  062 0993
LDL-C (mmol/l) 228  062 203  068* 025  063 195  070 192  056 003  075 0168
HDL-C (mmol/l) 151  024 157  038 006  032 154  027 148  034 006  025 0091
Waist circumference (cm) 8025  1012 7960  1047 065  157 7700  885 7614  888 086  090 0516
Hip circumference (cm) 9677  996 9625  1020 051  170 9382  864 9301  841 081  182 0479
All values are means  SD.
FPG, fasting plasma glucose; HOMA-IR, homeostasis model of assessment-insulin resistance; HOMA-B, homeostatic model assessment-beta-cell func-
tion; QUICKI, quantitative insulin sensitivity check index; VLDL-C, very low-density lipoprotein cholesterol; LDL-C, low-density lipoprotein choles-
terol; HDL-C, high-density lipoprotein cholesterol.
*Significant difference from baseline.
†Obtained from repeated measures ANOVA test (time 9 group interaction).
© 2014 John Wiley & Sons Ltd
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baseline levels of dependent variables along with characteristics
of study participants might provide some reasons for discrepant
findings. Increased expression of very long chain dehydrogenase
(VLCAD), medium chain acyl-CoA dehydrogenase (MCAD) and
b-oxidation gene expression after selenium intake may result in
increased lipid metabolism.33 In addition, in the present study,
within-group changes revealed a significant increase in serum
triglycerides and VLDL-C levels in the placebo group. This may
result from increased follicular fluid (FF) leptin and visfatin lev-
els.34 In addition, the stability in their diet and weight, and
short duration of the study, this seems unexpected, may influ-
ence lipid profiles. However, further research is required in this
area to confirm our findings.
Some limitations must be considered in the interpretation of
our findings. Due to limited funding, we did not examine the
effects of selenium supplementation on plasma or urine sele-
nium, inflammatory factors and PCOS relevant androgen levels.
Furthermore, our study was relatively of short duration of inter-
vention. Long-term interventions might result in greater changes
in circulating levels of lipid profiles. In addition, the beneficial
effects of selenium supplementation on the postprandial glyca-
emia and triglycerideamia would be of interest, and it is sug-
gested for a future study.
Taken together, 200 micrograms per day selenium supplemen-
tation for 8 weeks among PCOS women had beneficial effects
on insulin metabolism parameters, triglycerides and VLDL-C
levels; however, it did not affect FPG and other lipid profiles.
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